Mitochondrial 3-hydroxy-3-methylglutaryl-CoA synthase deficiency

Unique presenting laboratory values and a review of biochemical and clinical features

Erin Conboy, Filippo Vairo, Matthew Schultz, Katherine Agre, Ross Ridsdale, David R Deyle, Devin Oglesbee, Dimitar Gavrilov, Eric W Klee, Brendan Lanpher

Research output: Chapter in Book/Report/Conference proceedingChapter

2 Citations (Scopus)

Abstract

We report an 8-month-old infant with decreased consciousness after a febrile episode and reduced oral intake. He was profoundly acidotic but his lactate was normal. Serum triglycerides were markedly elevated and HDL cholesterol was very low. The urine organic acid analysis during the acute episode revealed a complex pattern of relative hypoketotic dicarboxylic aciduria, suggestive of a potential fatty acid oxidation disorder. MRI showed extensive brain abnormalities concerning for a primary energy deficiency. Whole exome sequencing revealed heterozygotic HMGCS2 variants. HMGCS2 encodes mitochondrial 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) synthase-2 (HMGCS2), which catalyzes the irreversible and rate-limiting reaction of ketogenesis in the mitochondrial matrix. Autosomal recessive HMG-CoA synthase deficiency (HMGCS2D) is characterized by hypoketotic hypoglycemia, vomiting, lethargy, and hepatomegaly after periods of prolonged fasting or illness. A retrospective analysis of the urine organic acid analysis identified 4-hydrox-6-methyl-2-pyrone, a recently reported putative biomarker of HMGCS2D. There was also a relative elevation of plasma acetylcarnitine as previously reported in one case. Our patient highlights a unique presentation of HMGCS2D caused by novel variants in HMGCS2. This is the first report of HMGCS2D with a significantly elevated triglyceride level and decreased HDL cholesterol level at presentation. Given this, we suggest that HMGCS2D should be considered in the differential diagnosis when hypertriglyceridemia, or low HDL cholesterol levels are seen in a child who presents with acidosis, mild ketosis, and mental status changes after illness or prolonged fasting. Although HMGCS2D is a rare disorder with nonspecific symptoms, with the advent of next-generation sequencing, and the recognition of novel biochemical biomarkers, the incidence of this condition may become better understood.

Original languageEnglish (US)
Title of host publicationJIMD Reports
PublisherSpringer
Pages63-69
Number of pages7
DOIs
StatePublished - Jan 1 2018

Publication series

NameJIMD Reports
Volume40
ISSN (Print)2192-8304
ISSN (Electronic)2192-8312

Fingerprint

Hydroxymethylglutaryl-CoA Synthase
HDL Cholesterol
Organic acids
Biomarkers
Fasting
Triglycerides
Urine
Acetylcarnitine
Exome
Lethargy
Ketosis
Acids
Hepatomegaly
Hypertriglyceridemia
Acidosis
Hypercholesterolemia
Consciousness
Hypoglycemia
Magnetic resonance imaging
Vomiting

Keywords

  • 3-Hydroxy-3-methylglutaryl-CoA
  • High-density lipoproteins
  • HMG-CoA synthase
  • HMG-CoA synthase deficiency
  • HMGCS2
  • Hypertriglyceridemia

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Biochemistry, Genetics and Molecular Biology (miscellaneous)

Cite this

Mitochondrial 3-hydroxy-3-methylglutaryl-CoA synthase deficiency : Unique presenting laboratory values and a review of biochemical and clinical features. / Conboy, Erin; Vairo, Filippo; Schultz, Matthew; Agre, Katherine; Ridsdale, Ross; Deyle, David R; Oglesbee, Devin; Gavrilov, Dimitar; Klee, Eric W; Lanpher, Brendan.

JIMD Reports. Springer, 2018. p. 63-69 (JIMD Reports; Vol. 40).

Research output: Chapter in Book/Report/Conference proceedingChapter

Conboy, Erin ; Vairo, Filippo ; Schultz, Matthew ; Agre, Katherine ; Ridsdale, Ross ; Deyle, David R ; Oglesbee, Devin ; Gavrilov, Dimitar ; Klee, Eric W ; Lanpher, Brendan. / Mitochondrial 3-hydroxy-3-methylglutaryl-CoA synthase deficiency : Unique presenting laboratory values and a review of biochemical and clinical features. JIMD Reports. Springer, 2018. pp. 63-69 (JIMD Reports).
@inbook{e3c7aa7ae8814a7a88264eb63aeb0e48,
title = "Mitochondrial 3-hydroxy-3-methylglutaryl-CoA synthase deficiency: Unique presenting laboratory values and a review of biochemical and clinical features",
abstract = "We report an 8-month-old infant with decreased consciousness after a febrile episode and reduced oral intake. He was profoundly acidotic but his lactate was normal. Serum triglycerides were markedly elevated and HDL cholesterol was very low. The urine organic acid analysis during the acute episode revealed a complex pattern of relative hypoketotic dicarboxylic aciduria, suggestive of a potential fatty acid oxidation disorder. MRI showed extensive brain abnormalities concerning for a primary energy deficiency. Whole exome sequencing revealed heterozygotic HMGCS2 variants. HMGCS2 encodes mitochondrial 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) synthase-2 (HMGCS2), which catalyzes the irreversible and rate-limiting reaction of ketogenesis in the mitochondrial matrix. Autosomal recessive HMG-CoA synthase deficiency (HMGCS2D) is characterized by hypoketotic hypoglycemia, vomiting, lethargy, and hepatomegaly after periods of prolonged fasting or illness. A retrospective analysis of the urine organic acid analysis identified 4-hydrox-6-methyl-2-pyrone, a recently reported putative biomarker of HMGCS2D. There was also a relative elevation of plasma acetylcarnitine as previously reported in one case. Our patient highlights a unique presentation of HMGCS2D caused by novel variants in HMGCS2. This is the first report of HMGCS2D with a significantly elevated triglyceride level and decreased HDL cholesterol level at presentation. Given this, we suggest that HMGCS2D should be considered in the differential diagnosis when hypertriglyceridemia, or low HDL cholesterol levels are seen in a child who presents with acidosis, mild ketosis, and mental status changes after illness or prolonged fasting. Although HMGCS2D is a rare disorder with nonspecific symptoms, with the advent of next-generation sequencing, and the recognition of novel biochemical biomarkers, the incidence of this condition may become better understood.",
keywords = "3-Hydroxy-3-methylglutaryl-CoA, High-density lipoproteins, HMG-CoA synthase, HMG-CoA synthase deficiency, HMGCS2, Hypertriglyceridemia",
author = "Erin Conboy and Filippo Vairo and Matthew Schultz and Katherine Agre and Ross Ridsdale and Deyle, {David R} and Devin Oglesbee and Dimitar Gavrilov and Klee, {Eric W} and Brendan Lanpher",
year = "2018",
month = "1",
day = "1",
doi = "10.1007/8904_2017_59",
language = "English (US)",
series = "JIMD Reports",
publisher = "Springer",
pages = "63--69",
booktitle = "JIMD Reports",

}

TY - CHAP

T1 - Mitochondrial 3-hydroxy-3-methylglutaryl-CoA synthase deficiency

T2 - Unique presenting laboratory values and a review of biochemical and clinical features

AU - Conboy, Erin

AU - Vairo, Filippo

AU - Schultz, Matthew

AU - Agre, Katherine

AU - Ridsdale, Ross

AU - Deyle, David R

AU - Oglesbee, Devin

AU - Gavrilov, Dimitar

AU - Klee, Eric W

AU - Lanpher, Brendan

PY - 2018/1/1

Y1 - 2018/1/1

N2 - We report an 8-month-old infant with decreased consciousness after a febrile episode and reduced oral intake. He was profoundly acidotic but his lactate was normal. Serum triglycerides were markedly elevated and HDL cholesterol was very low. The urine organic acid analysis during the acute episode revealed a complex pattern of relative hypoketotic dicarboxylic aciduria, suggestive of a potential fatty acid oxidation disorder. MRI showed extensive brain abnormalities concerning for a primary energy deficiency. Whole exome sequencing revealed heterozygotic HMGCS2 variants. HMGCS2 encodes mitochondrial 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) synthase-2 (HMGCS2), which catalyzes the irreversible and rate-limiting reaction of ketogenesis in the mitochondrial matrix. Autosomal recessive HMG-CoA synthase deficiency (HMGCS2D) is characterized by hypoketotic hypoglycemia, vomiting, lethargy, and hepatomegaly after periods of prolonged fasting or illness. A retrospective analysis of the urine organic acid analysis identified 4-hydrox-6-methyl-2-pyrone, a recently reported putative biomarker of HMGCS2D. There was also a relative elevation of plasma acetylcarnitine as previously reported in one case. Our patient highlights a unique presentation of HMGCS2D caused by novel variants in HMGCS2. This is the first report of HMGCS2D with a significantly elevated triglyceride level and decreased HDL cholesterol level at presentation. Given this, we suggest that HMGCS2D should be considered in the differential diagnosis when hypertriglyceridemia, or low HDL cholesterol levels are seen in a child who presents with acidosis, mild ketosis, and mental status changes after illness or prolonged fasting. Although HMGCS2D is a rare disorder with nonspecific symptoms, with the advent of next-generation sequencing, and the recognition of novel biochemical biomarkers, the incidence of this condition may become better understood.

AB - We report an 8-month-old infant with decreased consciousness after a febrile episode and reduced oral intake. He was profoundly acidotic but his lactate was normal. Serum triglycerides were markedly elevated and HDL cholesterol was very low. The urine organic acid analysis during the acute episode revealed a complex pattern of relative hypoketotic dicarboxylic aciduria, suggestive of a potential fatty acid oxidation disorder. MRI showed extensive brain abnormalities concerning for a primary energy deficiency. Whole exome sequencing revealed heterozygotic HMGCS2 variants. HMGCS2 encodes mitochondrial 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) synthase-2 (HMGCS2), which catalyzes the irreversible and rate-limiting reaction of ketogenesis in the mitochondrial matrix. Autosomal recessive HMG-CoA synthase deficiency (HMGCS2D) is characterized by hypoketotic hypoglycemia, vomiting, lethargy, and hepatomegaly after periods of prolonged fasting or illness. A retrospective analysis of the urine organic acid analysis identified 4-hydrox-6-methyl-2-pyrone, a recently reported putative biomarker of HMGCS2D. There was also a relative elevation of plasma acetylcarnitine as previously reported in one case. Our patient highlights a unique presentation of HMGCS2D caused by novel variants in HMGCS2. This is the first report of HMGCS2D with a significantly elevated triglyceride level and decreased HDL cholesterol level at presentation. Given this, we suggest that HMGCS2D should be considered in the differential diagnosis when hypertriglyceridemia, or low HDL cholesterol levels are seen in a child who presents with acidosis, mild ketosis, and mental status changes after illness or prolonged fasting. Although HMGCS2D is a rare disorder with nonspecific symptoms, with the advent of next-generation sequencing, and the recognition of novel biochemical biomarkers, the incidence of this condition may become better understood.

KW - 3-Hydroxy-3-methylglutaryl-CoA

KW - High-density lipoproteins

KW - HMG-CoA synthase

KW - HMG-CoA synthase deficiency

KW - HMGCS2

KW - Hypertriglyceridemia

UR - http://www.scopus.com/inward/record.url?scp=85058571392&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058571392&partnerID=8YFLogxK

U2 - 10.1007/8904_2017_59

DO - 10.1007/8904_2017_59

M3 - Chapter

T3 - JIMD Reports

SP - 63

EP - 69

BT - JIMD Reports

PB - Springer

ER -